Combination therapy using a chimeric antigen receptor

A method of treating a mesothelin expressing solid tumor in a subject in need thereof, the method comprising

• administering a therapeutically effective amount of T cells that express a chimeric antigen receptor (CAR) molecule that binds to mesothelin (“mesothelin CAR-expressing cells”) to the subject, and
• administering a chimeric serotype 5/3 oncolytic adenovirus comprising a nucleic acid molecule encoding a TNFα molecule and an IL-2 molecule to the subject, thereby treating the mesothelin expressing solid tumor, wherein the nucleic acid molecule comprises the sequence of SEQ ID NO:
• 612 and 614,
• wherein the subject is an immunocompetent human subject,
• wherein the CAR comprises the amino acid sequence of SEQ ID NO:
• 67;
• SEQ ID NO:
• 73, SEQ ID NO:
• 278, SEQ ID NO:
• 63, SEQ ID NO:
• 64, SEQ ID NO:
• 65, SEQ ID NO:
• 66, SEQ ID NO:
• 68, SEQ ID NO:
• 69, SEQ ID NO:
• 70, SEQ ID NO:
• 71, SEQ ID NO:
• 72, SEQ ID NO:
• 74, SEQ ID NO:
• 75, SEQ ID NO:
• 76, SEQ ID NO:
• 77, SEQ ID NO:
• 78, SEQ ID NO:
• 79, SEQ ID NO:
• 80, SEQ ID NO:
• 81, SEQ ID NO:
• 82, SEQ ID NO:
• 83, SEQ ID NO:
• 84, SEQ ID NO:
• 85, or SEQ ID NO:
• 86, each with or without the signal peptide MALPVTALLLPLALLLHAARP (SEQ ID NO:
• 1), and
• wherein the mesothelin CAR-expressing cells target a cell of the mesothelin expressing solid tumor systemically;
• and/or prevent the cell from egressing from the mesothelin expressing solid tumor.